Hybrid immunoglobulin-thrombolytic enzyme molecules which specif

Details Hybrid immunoglobulin-thrombolytic enzyme molecules which specif Hybrid immunoglobulin-thrombolytic enzyme molecules which specif

1993-07-26

1998-09-22

Nucker, Christine M.

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

4351722, 4351723, 4352523, 536 234, 536 2353, A61K 39395

Patent

active

058112650

ABSTRACT:
Hybrid immunoglobulin-enzyme molecules are provided which are composed of antibodies, or derivatives or fragments thereof, which specifically bind an arterial or venous thrombus that are operably linked to the enzymatically active portions of thrombolytic enzymes such as plasminogen activators. In a preferred embodiment the hybrid molecules specifically bind to fibrin and have fibrinolytic activity. The hybrid molecules of the present invention may be produced by any means, including chemical conjugation, or by means of recombinant DNA, genetic engineering and/or hybridoma technology. Methods for making and using the molecules in diagnosis and therapy are also disclosed.

REFERENCES:
patent: 4273873 (1981-06-01), Sugitachi et al.
patent: 4368149 (1983-01-01), Masuho et al.
patent: 4414148 (1983-11-01), Jansen et al.
patent: 4470925 (1984-09-01), Auditore-Hargreaves
patent: 4474893 (1984-10-01), Reading
patent: 4545988 (1985-10-01), Nakayama et al.
patent: 4600580 (1986-07-01), Smith
patent: 4671958 (1987-06-01), Rodwell et al.
patent: 4673573 (1987-06-01), Ferres et al.
patent: 4722903 (1988-02-01), Kudryk et al.
patent: 4758524 (1988-07-01), Bundesen et al.
patent: 4783330 (1988-11-01), Furie et al.
patent: 4833085 (1989-05-01), Schaumann et al.
patent: 4916070 (1990-04-01), Matsueda et al.
patent: 4927916 (1990-05-01), Matsueda et al.
patent: 5055289 (1991-10-01), Frincke et al.
patent: 5116613 (1992-05-01), Haber et al.
patent: 5256413 (1993-10-01), Haber et al.
patent: 5275812 (1994-01-01), Gold et al.
Haber, E., Antibody Targeting as a Strategy in Thrombolysis, in Monoclonal Antibodies in Cardiovascular Diseases (Khaw et al., eds.) Lea & Febiger, Philadelphia, pp. 187-197 (1994).
Runge et al., A Recombinant Chimeric Plasminogen Activator with High Affinity for Fibrin has Increased Thrombolytic Potency In Vitro and In Vivo, Proc. Natl. Acad. Sci. USA 88:10337-10341 (1991).
Tucker et al., Sequence of the Cloned Gene for the Constant Region of Murine .gamma.2b Immunoglobulin Heavy Chain, Science 206:1303-1306 (1979).
Lawn et al., The Nucleotide Sequence of the Human .beta.-Globin Gene, Cell 21:647-651 (1980).
Kabnick et al., Determinants that Contribute to Cytoplasmic Stability of Human c-fos and .beta.-Globin mRNAs are Located at Several Sites in Each mRNA, Molecular and Cellular Biology 8(8):3244-3250 (1988).
Morrison et al., Genetically Engineered Antibody Molecules, Advances in Immunology 44:65-92 (1989).
Haber et al., Antibody-Targeted Thrombolytic Agents, Japanese Circulation Journal 54:345-353 (1990).
Haber et al., Recombinant Production of Chimeric Fibrin Antibody-Fibrinolytic Enzyme Molecules for Use as Thrombolytic Agents, Chem. Abstracts 110:201, Abstract No. 110:109425h (1989).
Love et al., Recombinant Antibodies Possessing Novel Effector Functions, Methods in Enzymology 178:515-527 (1989).
Haber et al., Innovative Approaches to Plasminogen Activator Therapy, Science 243:51-56 (1989).
Runge et al., Plasminogen Activators, Circulation 79(2):217-224 (1989).
Runge et al., Increasing Selectivity of Plasminogen Activators with Antibodies, Clinical Research 36:501-506 (1988).
Runge et al., A Recombinant Molecule with Antifibrin Antibody and Single-Chain Urokinase Activities has Increased Fibrinolytic Potency, Circ. Suppl. II 78:II-509 (Abstract No. 2031) (1988).
Nelles et al., Characterization of a Fusion Protein Consisting of Amino Acids 1 to 263 of Tissue-Type Plasminogen Activator and Amino Acids 144 to 411 to Urokinase-Type Plasminogen Activator, Journal of Biological Chemistry 262(22):10855-10862 (1987).
Schnee et al., Construction and Expression of a Recombinant Antibody-Targeted Plasminogen Activator, Chemical Abstracts 107:158, Abstract No. 107:212913c (1987).
Schnee et al., Construction and Expression of a Recombinant Antibody-Directed Thrombolytic Molecule, Clinical Research 35(3):575A (1987).
Schnee et al., Construction and Expression of a Recombinant Antibody-Targeted Plasminogen Activator, Proc. Natl. Acad. Sci. USA 84:6904-6908 (1987).
Williams et al., Production of Antibody-Tagged Enzymes by Myeloma Cells: Application to DNA Polymerase I Klenow Fragment, Gene 43:319-324 (1986).
Neuberger et al., Recombinant Antibodies Possessing Novel Effect Functions, Nature 312:604-608 (1984).
Bode et al., Conjugation to Antifibrin Fab' Enhances Fibrinolytic Potency of Single-Chain Urokinase Plasminogen Activator, Circulation 81:1974-1980 (1990).
Collen et al., Thrombolytic and Pharmacokinetic Properties of Conjugates of Urokinase-type Plasminogen Activator with a Monoclonal Antibody Specific for Crosslinked Fibrin, Fibrinolysis 3:197-202 (1989).
Dewerchin et al., Biochemical Properties of Conjugates of Urokinase-Type Plasminogen Activator with a Monoclonal Antibody Specific for Cross-Linked Fibrin, Eur. J. Biochem. 185:141-149 (1989).
Charpie et al., Enhancement of Fibrinolysis by Single Chain Urokinase (scuPA) with a Bifunctional Antibody Having Both Fibrin and scuPA Specificities, Clinical Research 36(3):436A (1988).
Bode et al., Conjugation to an Antifibrin Antibody Enhances the Fibrinolytic Potency of Single-Chain Urokinase (scuPA), Clinical Research 36(3):203A (1988).
Runge et al., Conjugation to an Antifibrin Monoclonal Antibody Enhances the Fibrinolytic Potency of Tissue Plasminogen Activator In Vitro, Biochemistry 27:1153-1157 (1988).
Runge et al., Antibody-Enhanced Thrombolysis: Targeting of Tissue Plasminogen Activator In Vivo, Proc. Natl. Acad. Sci. USA 84:7649-7662 (1987).
Bode et al., Thrombolysis by a Fibrin-Specific Antibody Fab'-Urokinase Conjugate, J. Mol. Cell Cardiol. 19:335-341 (1987).
Bode et al., Characterization of an Antibody-Urokinase Conjugate, Journal of Biological Chemistry 262(22):10819-10823 (1987).
Runge et al., Tissue-Type Plasminogen Activator-Antifibrin Monoclonal Antibody Conjugate Enhances Clot Lysis in Plasma, Circulation 74 (Supp. II):II-246 (Abstract No. 984) (1986).
Runge et al., Tissue Type Plasminogen Activator Conjugated to an Antifibrin Monoclonal Antibody is a 10 Fold More Efficient Fibrinolytic Agent than Tissue Type Plasminogen Activator Alone, Clinical Research 34(2):469A (1986).
Sevilla et al., Plasminogen Activator-Anti-Human Fibrinogen Conjugate, Fed. Proc. 44:1073, Abstract No. 3872 (1985).
Ito et al., Fibrinolysis Studies: Fibrinogen-Specific Antibody as Carriers for Fibrinolytic Agents, Fed. Proc. 44:1846, Abstract No. 8382 (1985).
Sevilla et al., Plasminogen Activator-Anti-Human Fibrinogen Conjugate, Biochemical and Biophysical Research Communicatons 130(1):91-96 (1985).
Bode et al., Antibody-Directed Urokinase: A Specific Fibrinolytic Agent, Science 229:765-767 (1985).
Duberstein, R., Scientists Develop New Technique for Producing Bispecific Monoclonals, Genet. Eng. News 6(1):22-23 (1986).
Milstein et al., Hybrid Hybridomas and Their Use in Immunohistochemistry, Nature 305:537-540 (1983).
Kurokawa et al., Enhanced Fibrinolysis by a Bispecific Monoclonal Antibody Reactive to Fibrin and Tissue Plasminogen Activator, Bio/Technology 7:1163-1167 (1989).
Charpie et al., A Bispecific Antibody Enhances the Fibrinolytic Potency of Single-Chain Urokinase, Biochemistry 29(27):6374-6378 (1990).
Branscomb et al., Bispecific Monoclonal Antibodies Produced by Somatic Cell Fusion Increase the Potency of Tissue Plasminogen Activator, Thrombosis and Haemostasis 64(2):260-266 (1990).
Bode et al., Antibody-Directed Fibrinolysis, Journal of Biological Chemistry 264(2):944-948 (1989).
Runge et al., Antibody-Enhanced Thrombolysis: Capture of Tissue Plasminogen Activator by a Bispecific Antibody and Direct Targeting by an Antifibrin-Tissue Plasminogen Activator Conjugate In Vivo, Trans. Assoc. Am. Phys. 100:250-255 (1987).
Branscomb et al., Bispecific Antibodies that Bind Both Tissue Plasminogen Activator (t-PA) and Fibrin, Clinical Research 35(3):264A (1987).
Brennan et al., Preparation of Bispecific Antibodies by Chemical Recombination of Monoclonal Immunoglobulin G.sub.1 Fragments, Science 229:81-83 (1985).
Runge et al., Antibody Enhanced Thrombolysis: (1) Capture of Endogenous Tissue Plasminogen Activator (tPA) by a Heteroantibody D

Affiliated with

Also associated with

Rating

Hybrid immunoglobulin-thrombolytic enzyme molecules which specif does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hybrid immunoglobulin-thrombolytic enzyme molecules which specif, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hybrid immunoglobulin-thrombolytic enzyme molecules which specif will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1621129